After Immunogen and Sutro, Bristol buys into the folate story
The deal puts more support behind targeting folate receptor α, a long troubled target, with antibody-drug conjugates.
Sutro bucks the folate trend
Competing folate receptor-targeting projects have recorded one failure after another, but Sutro scores a phase I win.
Immunogen fails to leap Forward
As doubts grow about targeting the folate receptor, Immunogen’s decision to press on with mirvetuximab soravtansine looks desperate.